Bruce Fisch, MDField Physician
*Describe the progressive nature of CKD and its link to significant mortality and morbidity.
*Highlight the importance of screening and diagnosis for CKD.
*Discuss new treatment options for patients with CKD and T2D and supporting data from the DAPA-CKD trial.
This content was created by AstraZeneca healthcare professionals for use by healthcare professionals. AstraZeneca is committed to conducting business with the highest standards of integrity and professionalism. For further medical information requests and access to other AstraZeneca resources, please go to http://azmedical.com/ or please contact AstraZeneca at 1-877-893-1510. Please refer to the Farxiga Prescribing Information for further product information.